es-481
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2021 (NCT04714996)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
GRIP1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05234762 | Phase 2 | Nov 21, 2021 | ES Therapeutics Australia Pty Ltd |
| NCT04737174 | Phase 2 | Mar 25, 2021 | ES Therapeutics Australia Pty Ltd, Monash University |
| NCT04714996 | Phase 2 | Jan 31, 2021 | ES Therapeutics Australia Pty Ltd, Monash University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ES Therapeutics Australia Pty Ltd | For profit | 3 | 3 | 1 | 2021 |
| Monash University | Academic/Hospital | 2 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1